Skip to search formSkip to main contentSkip to account menu

dacetuzumab

A humanized monoclonal antibody directed against the CD40 receptor with potential antineoplastic activity. Dacetuzumab specifically binds to and… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Antibodies, Monoclonal, Humanized
NCIt Antineoplastic Agent Terminologyantigen binding

Narrower (1)

SGN 40

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development
Background: Immunotherapy for multiple myeloma (MM) has been the focus in recent years due to its myeloma-specific immune… 
2017
2017
Abstract 3647: Therapeutic activity of effector function-enhanced, non-fucosylated anti-CD40 antibodies in preclinical immune-competent rodent tumor models
Recent success of immune checkpoint inhibitors (CPIs) in the clinic underscores the role of cancer immune surveillance and the… 
Review
2016
Review
2016
Emerging antibodies for the treatment of multiple myeloma
ABSTRACT Introduction: Monoclonal antibodies mark the beginning of a new era in the context of multiple myeloma (MM) treatment… 
2011
2011
Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells
Non-Hodgkin lymphoma (NHL) is a genetically heterogeneous disease with several oncogenic events implicated in the transformation… 
2011
2011
Cancer Therapy : Preclinical Distinct Apoptotic Signaling Characteristics of the Anti-CD 40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma
Purpose: Individually targeting B-cell antigens with monoclonal antibody therapeutics has improved the treatment of non-Hodgkin… 
2009
2009
Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.
Abstract 2870 Poster Board II-846 Background: Dacetuzumab (SGN-40) is a humanized monoclonal antibody that targets CD40. In prior… 
2009
2009
A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.
Abstract 586 Background: Dacetuzumab (SGN-40), a humanized monoclonal antibody that targets CD40, mediates antitumor activity… 
2009
2009
Evaluation of a gene signature to predict single agent dacetuzumab (SGN-40) activity in patients with DLBCL.
11063 Background: Dacetuzumab (SGN-40) is a humanized IgG1 monoclonal antibody that binds to CD40, mediates effector cell… 
2009
2009
CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.
Abstract 2721 Poster Board II-697 The role of the CD40 pathway in B-cell cancers is rather enigmatic due to having polar opposite… 
2009
2009
Abstract #LB-138: A gene signature predicts sensitivity to the partial CD40 agonist, dacetuzumab (SGN-40), in patients with diffuse large B-cell lymphoma
Background: Agonism of the CD40 pathway represents a unique therapeutic opportunity for the treatment of diffuse large B-cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)